FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ADAMS R MARK					2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT]									(Chec	k all app Direc	licable) tor	ng Person(s) to Is 10% Ov		vner
(Last) 1165 EA	(Fir	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/07/2022									Officer (give title Other (spec below) below) Chief Operating Officer				specify
(Street) SEATTL	E WA	A 9	8109		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	Form	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(Sta		Zip)																
1. Title of Security (Instr. 3) 2. Transa Date				2. Transac	tion 2A. Deem Execution		Deemed ution Date,		3. Transaction Code (Instr. 8)					A) or 5. Am 5. Am Secu Bene		unt of	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
					((Month Day/Tear)		Code	v	Amount	(A) (D)	or Pric	Report Transa				1150. 4)	(Instr. 4)
Common Stock 07/07				07/07/2	2022		S ⁽¹⁾		825	D	\$	9.53	122,068			D			
Common Stock 07/08				07/08/2	2022				S ⁽²⁾		2,300 П		\$1	0.47	7 119,768			D	
		Tal									osed of, convertib				Owne	d			
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Ov Fo Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Shares	r					

Explanation of Responses:

Remarks:

/s/ R. Mark Adams by Eric Billings, attorney-in-fact

07/08/2022

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

^{2.} The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.